Emerging research suggest this peptide, a dual agonist targeting both incretin and GIP , appears to provide a promising advancement for weight treatment. Initial patient trials have shown considerable https://getretatrutideaustralia.com/blog/retatrutide-vs-tirzepatide-semaglutide